Horizon Pharma (HZNP) Tops Q3 EPS by 15c, Offers Guidance

November 6, 2019 7:16 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Horizon Pharma (NASDAQ: HZNP) reported Q3 EPS of $0.64, $0.15 better than the analyst estimate of $0.49. Revenue for the quarter came in at $665.5 million versus the consensus estimate of $329.76 million.


Horizon Pharma sees Q4 2019 revenue of $1.28-1.3 billion, versus the consensus of $1.28 billion.

  • The Company now expects full-year 2019 adjusted EBITDA to range between $465 million and $475 million, versus the previous guidance range of $460 million to $475 million.

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities